Consistent with the general breast cancer population in Korea, 22 (59.5%) patients with HER2+ MBC were HR-positive at initial diagnosis, and 16 (43.2%) were still HR-positive when the disease metastasized (Figure 2) [2]. This evidence concerns the gene ERBB2 and breast carcinoma.